Abrocitinib, sold under the brand name Cibinqo, is a Janus kinase inhibitor medication used for the treatment of atopic dermatitis (eczema). It was developed by Pfizer. Medical uses
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Side effects
The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea. Pharmacology
Mechanism of action
It is a selective inhibitor of the enzyme janus kinase 1 (JAK1). Pharmacokinetics
Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine. History
April 2016: initiation of Phase 2b trial
December 2017: initiation of JADE Mono-1 Phase 3 trial
May 2018: Results of Phase 2b trial posted
October 2019: Results of Phase 3 trial presented
June 2020: Results of second Phase 3 trial published

Society and culture
Legal status
In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis.In January 2022, the United States Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis. References
External links
"Abrocitinib". Drug Information Portal. U.S. National Library of Medicine.
Speech therapy- Therapy to help someone speak more clearly, swallow more safely, or use a communication device such as a DynaVox
Medication- Certain medications can reduce stiffness from overactive muscles and decrease pain. Examples are botulinum toxin or baclofen, with the latter delivered orally or via an intrathecal pump. Surgery- In some cases, orthopedic and/or neurological surgeries are recommended when pain and stiffness interfere with participation in meaningful activities and other treatments are not effective. Prognosis
Every case of spastic cerebral palsy is different. Some people with this type of CP can accomplish activities of daily living independently, while some need the assistance of a personal care aide for certain tasks, and others need 24-hour support. About 1/3 of people with cerebral palsy cannot walk, about 1/2 have intellectual disabilities, and 3/4 experience some level of chronic pain. There is limited research on adults with spastic CP. The brain injury causing CP does not progress or change, but the functional impact and thus, ones needs may change with age.Some issues specific to adults with spastic and other forms of cerebral palsy are:

Premature aging
Fatigue
Pain
Arthritis
Depression and anxiety
Post impairment syndromeRegardless of their particular expression of spastic cerebral palsy, affected individuals can lead fulfilling lives. Improved physical accessibility in society and increased social acceptance can increase community participation. Workforce participation of people with CP has almost doubled in the last four decades. Social inclusion and the presence or absence of policy to address discrimination, in addition to medical intervention, influences the outlook for people living with spastic cerebral palsy.